Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions

Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: 109, P. 44 - 66

Published: Jan. 9, 2025

Language: Английский

---

Advancing clinical biochemistry: addressing gaps and driving future innovations

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: April 8, 2025

Modern healthcare depends fundamentally on clinical biochemistry for disease diagnosis and therapeutic guidance. The discipline encounters operational constraints, including sampling inefficiencies, precision limitations, expansion difficulties. Recent advancements in established technologies, such as mass spectrometry the development of high-throughput screening point-of-care are revolutionizing industry. biosensor technology wearable monitors facilitate continuous health tracking, Artificial Intelligence (AI)/machine learning (ML) applications enhance analytical capabilities, generating predictive insights individualized treatment protocols. However, concerns regarding algorithmic bias, data privacy, lack transparency decision-making ("black box" models), over-reliance automated systems pose significant challenges that must be addressed responsible AI integration. limitations remain-substantial implementation expenses, system incompatibility issues, information security vulnerabilities intersect with ethical considerations fairness protected information. Addressing these demands coordinated efforts between clinicians, scientists, technical specialists. This review discusses current biochemistry, explicitly addressing reference intervals barriers to implementing innovative biomarkers medical settings. discussion evaluates how advanced technologies multidisciplinary collaboration can overcome constraints while identifying research priorities diagnostic accessibility better delivery.

Language: Английский

---

Zanubrutinib and Pterostilbene Intervention in Acute Lymphoblastic Leukemia: An Action Mechanism Unveiled by Network Pharmacology and Machine Learning

BIO Web of Conferences, Journal Year: 2025, Volume and Issue: 172, P. 02005 - 02005

Published: Jan. 1, 2025

Zanubrutinib, a BTK inhibitor, and pterostilbene, natural anticancer compound, show potential in combination therapy for Acute Lymphoblastic Leukemia (ALL). Analyzing over 12,000 genes associated with ALL, key hub proteins like LYN, BTK, MYD88, SYK were identified as crucial leukemia progression. Pathway analyses revealed their role immune signaling, including B-cell receptor signaling. Zanubrutinib pterostilbene complement each other by targeting these pathways, inhibiting cell growth promoting apoptosis. This study highlights the importance of network pharmacology machine learning developing optimized, targeted treatments ALL.

Language: Английский

---

CircRNAs in the Tumor Microenvironment: New Frontiers in Cancer Progression and Therapy

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: 212, P. 104754 - 104754

Published: May 2, 2025

Language: Английский

---

Advancement and Challenges in Monitoring of CAR-T Cell Therapy: A Comprehensive Review of Parameters and Markers in Hematological Malignancies

Cancers, Journal Year: 2024, Volume and Issue: 16(19), P. 3339 - 3339

Published: Sept. 29, 2024

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment for relapsed/refractory B-cell lymphomas. Despite its success, this is accompanied by a significant frequency of adverse events, including cytokine release syndrome (CRS), immune-effector-cell-associated neurotoxicity (ICANS), or cytopenias, reaching even up to 80% patients following CAR-T cell therapy. CRS results from uncontrolled overproduction proinflammatory cytokines, which leads symptoms such as fever, headache, hypoxia, neurological complications. detection possible use flow cytometry (FC) quantitative polymerase chain reaction (qPCR) assays, two primary techniques used evaluation in peripheral blood, bone marrow (BM), and cerebrospinal fluid (CSF). State-of-the-art imaging technologies play crucial role monitoring distribution persistence cells clinical trials. Still, they can also be extended with FC digital PCR (dPCR). Monitoring changes populations during disease progression gives an important insight into how response develops on cellular level. It help improve therapeutic design optimize make it more precise personalized, overcoming problem tumor relapse.

Language: Английский

---

Leucemias: Um Panorama Geral das Manifestações Clínicas, Abordagens Diagnósticas e Estratégias de Tratamento

Brazilian Journal of Implantology and Health Sciences, Journal Year: 2024, Volume and Issue: 6(8), P. 3714 - 3724

Published: Aug. 22, 2024

Introdução: As leucemias são neoplasias hematológicas que se originam na medula óssea e causam proliferação descontrolada de células precursoras hematopoiéticas. Classificadas em agudas crônicas, as variam progressão tratamento. O diagnóstico precoce o uso exames laboratoriais tecnologias avançadas essenciais para personalizar tratamento, evoluiu com terapias direcionadas CAR-T. Metodologia: Este estudo revisou artigos 2014 a 2024, encontrados bases como PubMed SCIELO, utilizando palavras-chave dos Descritores Ciências da Saúde (DeCS). Os selecionados abordavam manifestações clínicas, diagnóstico, tratamento leucemias, foco recentes. A análise crítica avaliou qualidade metodológica aplicabilidade prática achados no manejo das leucemias. Resultados: avanços têm melhorado significativamente os desfechos pacientes, personalização abordagens terapêuticas sendo fundamental. Técnicas citometria fluxo, PCR, NGS permitem uma caracterização detalhada identificando mutações genéticas guiam Terapias inovadoras, TKIs CAR-T, mostraram-se eficazes, embora desafios toxicidade, resistência, custos elevados ainda precisem ser enfrentados melhorar acesso manejo. Considerações Finais: complexas, NGS, TKIs, melhoraram prognóstico. Apesar disso, prognóstico depende fatores subtipo, idade, mutações, toxicidade custo.

---

Immunonkologie

Deleted Journal, Journal Year: 2024, Volume and Issue: 30(10), P. 952 - 958

Published: Oct. 1, 2024

Die Idee, das körpereigene Immunsystem für die Krebstherapie zu nutzen, geht auf 18. Jahrhundert zurück. Doch erst in den letzten Jahren gelang es, Immunonkologie als wesentliche Therapiesäule der etablieren. Der Beitrag erläutert aktuelle immunonkologische Standards solider Tumoren, adressiert innovative Therapien und Kombinationsstrategien diskutiert Zukunftsstrategien Weiterentwicklungen. Immunonkologika sind eine wichtige Säule modernen Therapie Tumoren. Dazu haben vor allem Immuncheckpointinhibitoren beigetragen, bei nahezu allen Entitäten Teil Standardtherapie sind. Dennoch Ansprechraten weiterhin unbefriedigend, auch aufgrund von Nebenwirkungen Resistenzmechanismen. Daher ist es essenziell, durch Kombinationstherapien präzisionsimmunologische Ansätze weiterzuentwickeln genetische immunologische Profile des Tumorgewebes entsprechende Wirtsfaktoren maßgeschneiderte effektivere nutzen. Zelluläre Antikörper-basierte Therapien, Vakzinierungen sowie Kombinationen mit Zytokinen Immunmodulatoren dabei vielversprechende Ansätze. Zudem Entwicklung prädiktiver Biomarker um optimierte Therapiesteuerung, Sequenzen Identifizierung erfolgversprechender Subgruppen ermöglichen. Multimodale KI(künstliche Intelligenz)-Modelle bieten attraktive Optionen, multiple Datensätze integrieren. hat enormes Potenzial, im Kontext personalisierten Onkologie neue Behandlungsansätze effektivere, individualisierte Biomarker-gestützte Therapiekonzepte entwickeln.

---

Clinical Significance of Complement and Coagulation Cascades Genes for Patients With Acute Lymphoblastic Leukemia

International Journal of Laboratory Hematology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 10, 2024

Acute lymphoblastic leukemia (ALL) is the second most common acute in adults and 5-year survival remains low.

Language: Английский

---